Tag Archives: FLXN

Analysts Expect Flexion Therapeutics (FLXN) Will Announce Quarterly Sales of $4.43 Million

Equities analysts expect that Flexion Therapeutics (NASDAQ:FLXN) will post sales of $4.43 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Flexion Therapeutics’ earnings. The lowest sales estimate is $2.69 million and the highest is $7.40 million. The firm is expected to announce its next earnings results on Tuesday, August 14th.

According to Zacks, analysts expect that Flexion Therapeutics will report full-year sales of $26.40 million for the current year, with estimates ranging from $20.40 million to $41.70 million. For the next fiscal year, analysts expect that the business will report sales of $126.46 million per share, with estimates ranging from $100.00 million to $175.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Flexion Therapeutics.

Get Flexion Therapeutics alerts:

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.33) by $0.23. The company had revenue of $2.19 million during the quarter, compared to analyst estimates of $1.99 million.

A number of research firms have commented on FLXN. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (down previously from $37.00) on shares of Flexion Therapeutics in a research report on Friday, March 9th. BidaskClub raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 27th. ValuEngine raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, April 27th. Wells Fargo reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Thursday, April 26th. Finally, Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $99.00.

NASDAQ FLXN traded up $0.78 during trading hours on Friday, reaching $25.78. The company had a trading volume of 752,573 shares, compared to its average volume of 722,904. Flexion Therapeutics has a 1-year low of $16.51 and a 1-year high of $32.25. The company has a debt-to-equity ratio of 0.67, a current ratio of 15.57 and a quick ratio of 12.96. The stock has a market capitalization of $957.11 million, a P/E ratio of -6.20 and a beta of 0.82.

A number of large investors have recently modified their holdings of FLXN. Schwab Charles Investment Management Inc. increased its stake in Flexion Therapeutics by 6.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 107,550 shares of the specialty pharmaceutical company’s stock worth $2,601,000 after purchasing an additional 6,336 shares during the period. Berson & Corrado Investment Advisors LLC purchased a new stake in Flexion Therapeutics during the fourth quarter worth about $324,000. Peregrine Capital Management LLC increased its stake in Flexion Therapeutics by 11.4% during the fourth quarter. Peregrine Capital Management LLC now owns 662,875 shares of the specialty pharmaceutical company’s stock worth $16,598,000 after purchasing an additional 67,664 shares during the period. Legato Capital Management LLC purchased a new stake in Flexion Therapeutics during the fourth quarter worth about $447,000. Finally, Perkins Capital Management Inc. purchased a new stake in Flexion Therapeutics during the fourth quarter worth about $1,340,000. Institutional investors own 94.19% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com